Log in

NYSEAMERICAN:OGENOragenics Stock Price, Forecast & News

$0.92
-0.12 (-11.54 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.90
Now: $0.92
$1.05
50-Day Range N/A
52-Week Range
$0.35
Now: $0.92
$2.09
Volume3.92 million shs
Average Volume4.69 million shs
Market Capitalization$50.93 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OGEN
CUSIPN/A
Phone+1-813-2867900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$50.93 million
Next Earnings DateN/A
OptionableNot Optionable
$0.92
-0.12 (-11.54 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Oragenics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Oragenics
.

How were Oragenics' earnings last quarter?

Oragenics Inc (NYSEAMERICAN:OGEN) announced its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.03.
View Oragenics' earnings history
.

When did Oragenics' stock split? How did Oragenics' stock split work?

Oragenics shares reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for OGEN?

1 brokerages have issued twelve-month target prices for Oragenics' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Oragenics' stock price to reach $2.00 in the next year. This suggests a possible upside of 117.4% from the stock's current price.
View analysts' price targets for Oragenics
.

Has Oragenics been receiving favorable news coverage?

Headlines about OGEN stock have been trending extremely negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oragenics earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
View the latest news about Oragenics
.

Are investors shorting Oragenics?

Oragenics saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,310,000 shares, an increase of 18.0% from the April 30th total of 1,110,000 shares. Based on an average daily trading volume, of 2,820,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 3.6% of the company's stock are sold short.
View Oragenics' Short Interest
.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

Who are Oragenics' major shareholders?

Oragenics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sara Bay Financial (2.39%) and Integrated Wealth Concepts LLC (0.15%). Company insiders that own Oragenics stock include Family Lp Koski and Robert C Koski.
View institutional ownership trends for Oragenics
.

Which major investors are buying Oragenics stock?

OGEN stock was bought by a variety of institutional investors in the last quarter, including Sara Bay Financial, and Integrated Wealth Concepts LLC.
View insider buying and selling activity for Oragenics
.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.92.

How big of a company is Oragenics?

Oragenics has a market capitalization of $50.93 million. Oragenics employs 6 workers across the globe.

What is Oragenics' official website?

The official website for Oragenics is www.oragenics.com.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.